PDCD1 and cancer: Responsiveness to checkpoint inhibitors (mainly PD-1/PD-L1 (programmed cell death protein-1/programmed cell death protein ligand 1) and CTLA4 (cytotoxic T cell antigen)) is the key to successful cancer therapy, but still not every patient achieves clinical benefit [38].